# PharmaCyte Biotech, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/PharmaCyte Biotech, Inc.). ## Overview PharmaCyte Biotech, Inc. is a U.S.-based biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box® live-cell encapsulation platform. The company’s current product candidate family includes CypCaps™, with development centered on therapies for pancreatic cancer and other oncology indications. ## Products & services • Cell-in-a-Box® live-cell encapsulation technology • CypCaps™ cellular therapy product candidate • Pancreatic cancer therapy development • LAPC-focused clinical development programs • Preclinical and regulatory support services - **Cellular therapy platform** (70%) — Encapsulated live-cell technologies designed to activate cancer prodrugs near tumors. - **Lead oncology product candidate** (20%) — CypCaps™ and related encapsulated-cell product candidates for pancreatic cancer. - **Preclinical and translational development** (10%) — Research, assay development, and nonclinical work supporting IND-enabling studies. - Cell-in-a-Box® live-cell encapsulation technology - CypCaps™ cellular therapy product candidate - Pancreatic cancer therapy development - LAPC-focused clinical development programs - Preclinical and regulatory support services ## Customers PharmaCyte Biotech does not currently sell commercial products; its primary counterparties are regulators, clinical investigators, consultants, and potential future licensing partners. If its product candidates are approved, the intended end customers would be oncology patients treated through hospitals, cancer centers, and pharmaceutical commercialization partners. - **Regulatory authorities** (primary) — FDA and comparable agencies review INDs, clinical holds, and trial packages for the company's oncology programs. - **Clinical investigators and trial sites** (primary) — Hospitals, physicians, and research sites conduct preclinical and clinical studies for LAPC and related programs. - **Potential licensing partners** (secondary) — Large pharmaceutical companies may license approved product candidates for commercialization. - **Future oncology patients** (emerging) — Patients with pancreatic cancer and other cancers would be treated if the therapies reach market. - Regulators such as the FDA for IND review and clinical hold resolution - Clinical investigators and trial sites running oncology studies - Consultants and service providers supporting R&D and regulatory work - Potential pharmaceutical licensees for future commercialization - Hospitals and cancer centers as eventual treatment delivery sites ## Geography The company is headquartered in Las Vegas, Nevada and is incorporated in the United States. Its business is primarily U.S.-based, with regulatory and clinical development activities tied to U.S. healthcare and FDA oversight; any future commercialization could also involve foreign regulators such as the EMA. - Headquartered in Las Vegas, Nevada - Incorporated in Nevada, United States - Primary regulatory exposure is to the FDA and U.S. healthcare laws - Clinical development is centered on U.S.-based oncology programs - Future commercialization could extend to Europe through EMA pathways ## Strategy The company’s strategy is to advance its Cell-in-a-Box® platform through regulatory clearance and clinical development for pancreatic cancer, especially LAPC. It also appears to be reassessing its technology and partner dependencies while preserving optionality for licensing or collaboration if a product candidate reaches approval. - **Clear the FDA clinical hold on LAPC** (short-term) — Regulatory clearance is required before the planned pancreatic cancer trial can proceed. - **Advance the Cell-in-a-Box® oncology platform** (medium-term) — The platform is the core technology underpinning the company's product candidates. - **Preserve commercialization flexibility** (medium-term) — The company may need a licensing or partnership route to bring any approved therapy to market. - Resolve the FDA clinical hold on the LAPC program - Advance Cell-in-a-Box®-based oncology candidates - Use consultants and external experts to run R&D efficiently - Evaluate partner and licensing structures for commercialization - Reassess technology dependencies and patent/know-how access ## Risks PharmaCyte Biotech faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, manufacturing complexity, and dependence on external capital. Company-specific risks include the FDA clinical hold, dependence on SG Austria-related technology and know-how, and potential IP disputes or expirations that could impair the platform. - **FDA clinical hold on the LAPC program** [high] — The planned pancreatic cancer trial cannot proceed until requested studies and responses are accepted. - **Dependence on SG Austria technology and know-how** [high] — The company disclosed that licensed patents have expired and know-how resides with SG Austria. - **Clinical and preclinical failure** [high] — Oncology programs may fail to show safety, efficacy, or manufacturability in trials. - **Biologics manufacturing complexity** [medium] — Cell-based products require specialized facilities, quality controls, and validated processes. - **Dilution and financing risk** [high] — The company expects to need additional capital and may rely on equity, debt, or partnerships. - **Nasdaq listing compliance risk** [medium] — A sustained low share price could lead to delisting and reduce liquidity for investors. - FDA clinical hold can delay or block the LAPC program - Dependence on SG Austria for know-how and licensed technology - Biologics manufacturing is complex and hard to scale - Clinical trial outcomes may show safety or efficacy issues - Capital needs may force dilutive financing or partnerships ## Accounting The company’s financial reporting is dominated by judgmental estimates rather than operating revenue recognition, since it has no revenues. Investors should watch fair value measurements for financial instruments, impairment testing for indefinite-lived intangible assets, and stock-based compensation, all of which can materially affect reported losses in a development-stage biotech. - **Fair value of financial instruments** — Can affect reported gains, losses, and balance sheet values - **Impairment of indefinite-lived intangible assets** — Can create non-cash charges and reduce asset carrying values - **Stock-based compensation** — Can materially affect operating expenses and net loss - **Related-party service agreements** — Requires careful disclosure and expense classification - **No revenue and development-stage expense profile** — Quarterly comparability is driven by project timing rather than sales seasonality - No revenue means results are driven by operating expense timing - Fair value estimates affect financial instruments and other measurements - Indefinite-lived intangible assets are tested for impairment - Stock-based compensation can move with option valuation assumptions - Related-party service agreements affect expense recognition --- *Last updated: 2026-04-29T04:48:34.013278+00:00*